Why the study?
A growing body of evidence highlights key roles of adenosine 2A receptor in obesity and related diseases, prompting a summary to clarify its complicated impacts.
What are the pathophysiological roles of the adenosine 2A receptor in obesity and related diseases?
What are the pathophysiological roles of the adenosine 2A receptor in obesity and related diseases?
The adenosine 2A receptor plays key pathophysiological roles in obesity and its associated comorbidities, including NAFLD, diabetes, and atherosclerosis.
May warrant adenosine receptor targeting in obesity-related disease; leaves open need for clinical validation.
Summary Obesity, a burgeoning worldwide health system challenge, is associated with several comorbidities, including non‐alcoholic fatty liver disease (NAFLD), diabetes, atherosclerosis, and osteoarthritis, leading to serious problems to people's health. Adenosine is a critical extracellular signaling molecule that has essential functions in regulating most organ systems by binding to four G‐protein‐coupled adenosine receptors, denoted A 1 , A 2A , A 2B , and A 3 . Among the receptors, a growing body evidence highlights the key roles of the adenosine 2A receptor (A 2A R) in obesity and related diseases. In the current review, we summarize the effects of A 2A R in obesity and obesity‐associated non‐alcoholic fatty liver disease, diabetes, atherosclerosis, and osteoarthritis, to clarify the complicated impacts of A 2A R on obesity and related diseases.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: